CannaPacific subsidiary e3D Pharma has announced a research partnership with the University of New South Wales (UNSW) using translational models to examine the use of cannabinoids to treat post-traumatic stress disorder (PTSD) and anxiety.
The company’s pharmaceutical development team are producing high-purity actives, isolated from in-house developed cannabis strains, and are working with UNSW to evaluate their pharmacological role in memory consolidation within the treatment of PTSD.
The eventual aim is to develop new authorised medicines.
Chief scientific officer Tim Bowser said: “The human endocannabinoid system plays an important role in emotional responses such as fear and memory. The team at e3D Pharma are committed to high-quality science to fill the existing gaps in understanding the clinical effectiveness of cannabinoid-based medicines.”
UNSW Professor Rick Richardson added: “We examine a broad range of topics, including the behavioural and neural processes involved in fear expression and inhibition, pharmacological adjuncts to enhance fear loss, and the effects of early life stress on physical and emotional development.
“Our overarching aim is to gain a better understanding of learning and memory, and conduct our research in a way that has potential translational value for understanding anxiety disorders.”
